Publicaciones en colaboración con investigadores/as de Netherlands Cancer Institute (18)

2024

  1. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)

    European Journal of Cancer, Vol. 204

2023

  1. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe

    European Journal of Cancer, Vol. 185, pp. 28-39

  2. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial

    Annals of surgery, Vol. 278, Núm. 4, pp. e766-e772

  3. The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer—results from the RAPIDO trial

    ESMO Open, Vol. 8, Núm. 2

2022

  1. ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe

    Annals of Oncology, Vol. 33, Núm. 11, pp. 1119-1133

2021

  1. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 1, pp. 29-42

2020

  1. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial

    Radiotherapy and Oncology, Vol. 147, pp. 75-83

  2. Erratum to “Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial” [Radiother. Oncol. 147 (2020) 75–83] (Radiotherapy and Oncology (2020) 147 (75–83), (S0167814020301201), (10.1016/j.radonc.2020.03.011))

    Radiotherapy and Oncology

  3. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

    Annals of Oncology, Vol. 31, Núm. 10, pp. 1320-1335

  4. The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper

    Radiotherapy and Oncology

2019

  1. Definition of the rectum: An International, expert-based Delphi consensus

    Annals of Surgery, Vol. 270, Núm. 6, pp. 955-959

2017

  1. Phase Ib study of lumretuzumab plus cetuximab or erlotinib in solid tumor patients and evaluation of HER3 and heregulin as potential biomarkers of clinical activity

    Clinical Cancer Research, Vol. 23, Núm. 18, pp. 5406-5415

2016

  1. Biosimilars: A position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers

    ESMO Open, Vol. 1, Núm. 6

  2. Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)

    ESMO Open, Vol. 1, Núm. 6

  3. First-in-human phase i study of lumretuzumab, a glycoengineered humanized anti-HER3 monoclonal antibody, in patients with metastatic or advanced HER3-positive solid tumors

    Clinical Cancer Research, Vol. 22, Núm. 4, pp. 877-885

  4. Treatment sequence of synchronously (liver) metastasized colon cancer

    Digestive and Liver Disease, Vol. 48, Núm. 10, pp. 1119-1123

2012

  1. Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe

    European Journal of Cancer, Vol. 48, Núm. 2, pp. 159-169

1993

  1. Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells

    British Journal of Cancer, Vol. 68, Núm. 5, pp. 898-908